| Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis G Ritchie, H Gasper, J Man, S Lord, I Marschner, M Friedlander, CK Lee JAMA oncology 4 (4), 522-528, 2018 | 110 | 2018 |
| Epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) C O’Leary, H Gasper, KB Sahin, M Tang, A Kulasinghe, MN Adams, ... Pharmaceuticals 13 (10), 273, 2020 | 55 | 2020 |
| Spatial profiling technologies and applications for brain cancers P Kalita-de Croft, H Sadeghi Rad, H Gasper, K O’Byrne, SR Lakhani, ... Expert review of molecular diagnostics 21 (3), 323-332, 2021 | 16 | 2021 |
| COVID-19 and the cancer care workforce: from doctors to ancillary staff H Gasper, E Ahern, N Roberts, B Chan, Z Lwin, MCCCQ Research Seminars in Oncology 47 (5), 309-311, 2020 | 10 | 2020 |
| Resilience and ongoing quality care for cancer clinical trials during COVID‐19: experience from a tertiary hospital in Australia A Ives, T Pusztai, J Keller, E Ahern, B Chan, H Gasper, D Wyld, ... Asia‐Pacific Journal of Clinical Oncology 18 (2), e141-e147, 2022 | 5 | 2022 |
| Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers? G Ritchie, H Gasper, J Man, S Lord, M Friedlander, C Lee, I Marschner Annals of Oncology 28, v411, 2017 | 3 | 2017 |
| Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia H Gasper, E Ahern, N Roberts, B Chan, B Hughes, G Kennedy, D Wyld, ... BMJ open 11 (5), e044655, 2021 | 1 | 2021 |
| An extraordinary response to dual immune checkpoint inhibitor and vascular endothelial growth factor inhibition in a patient with hepatocellular carcinoma and follicular lymphoma. ZH Hong, M Dickey, P Wong, H Gasper Internal Medicine Journal 53 (6), 2023 | | 2023 |
| From doctors to ancillary staff: Regional and metropolitan cancer workforce perceptions and distress resulting from COVID-19 pandemic adaptations NA Roberts, E Ahern, A Pelecanos, H Gasper, B Chan, Z Lwin Seminars in Oncology 49 (6), 490-496, 2022 | | 2022 |
| Drug-Specific Orofacial Complications of Novel Anti-cancer Therapies HM Gasper, J Sanmugarajah Orofacial Supportive Care in Cancer: A Contemporary Oral Oncology …, 2022 | | 2022 |
| Psychosocial impacts of COVID-19 upon a diverse Australian oncology workforce: From doctors to ancillary staff. ES Ahern, NA Roberts, BA Chan, HM Gasper, A Pelecanos, G Kennedy, ... Journal of Clinical Oncology 39 (15_suppl), e23016-e23016, 2021 | | 2021 |
| Caregiver burden and experience of an Australian geriatric oncology population during COVID-19 pandemic H Gasper, E Ahern, N Roberts, H Wheatley, P McGuire, D Wyld, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 16, 148-148, 2020 | | 2020 |
| The role of a geriatric oncology service in building resilience during the COVID-19 pandemic H Gasper, E Ahern, N Roberts, H Wheatley, P McGuire, D Wyld, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 16, 147-148, 2020 | | 2020 |
| Psychosocial impacts of COVID-19 on oncology workforces: Metro versus regional Australia. ES Ahern, HM Gasper, B Chan, NA Roberts, BGM Hughes, D Wyld, ... Journal of Clinical Oncology 38 (29_suppl), 111-111, 2020 | | 2020 |
| Emotional impact of COVID-19 preparations on metro and regional cancer workforces in Queensland Australia: "We are all in this together". NA Roberts, B Chan, ES Ahern, HM Gasper, G Kennedy, BGM Hughes, ... Journal of Clinical Oncology 38 (29_suppl), 44-44, 2020 | | 2020 |
| Evaluation of a virtual meeting platform for state-wide oncology education during the COVID-19 pandemic V Andelkovic, W Xu, H Gasper, NB Oliveira, K Middleton, S Feng, ... Asia-Pacific Journal of Clinical Oncology 16 (S8), 158, 2020 | | 2020 |
Elizabeth AhernMonash Health and Monash University在 monash.edu 的电子邮件经过验证
